Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd
ASX:RGS ISIN:AU000000RGS6
新闻
Regeneus (ASX:RGS), 一家临床阶段再生医药公司,今天宣布开始其犬类癌症疫苗技术Kvax试验,结合化学疗法治疗犬类淋巴瘤。
###
231,242 公司背景浏览
- 本页浏览人次: (过去7日: 84) (过去30日: 349) (自发布以来: 26867)